12:50 AM EDT, 10/14/2026 (MT Newswires) -- Medincell (MEDCL.PA) secured 13.8 million euros of additional non-dilutive financing on market terms, according to a Tuesday filing. The biopharmaceutical company said it obtained the financing from Bpifrance and unnamed European commercial banks. Medincell's debt maturity profile has been extended to September 2031.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.